reduction ki num benign breast tissue high risk women lignan secoisolariciresinol diglycoside sdg abstract preclinical correlative studies suggest reduced breast cancer higher lignan intake blood levels conducted pilot study modulation risk biomarkers breast cancer premenopausal women administration plant lignan secoisolariciresinol diglycoside sdg eligibility criteria included regular menstrual cycles oral contraceptives greater num fold increase num year risk baseline ki num num areas hyperplasia breast tissue sampled random periareolar fine needle aspiration rpfna follicular phase menstrual cycle sdg num mg daily num months repeat rpfna primary endpoint change ki num secondary endpoints included change cytomorphology mammographic breast density serum bioavailable estradiol testosterone igf-i igfbp num plasma lignan levels forty-five num eligible women completed study excellent compliance median num side effects num grade num median plasma enterolactone increased num fold total lignans num fold thirty-six num num evaluable subjects demonstrated decrease ki num median num range num num num range num num num wilcoxon signed rank test decrease baseline proportion women atypical cytology num observed based favorable risk biomarker modulation lack adverse events initiating randomized trial sdg placebo premenopausal women 
